The latest issue of Nature Medicine features a recap (freely available) of a study performed by Deloitte about phase 2 clinical trials and the consequences of doing them right. Or wrong. Keep reading below for the full details.
To make the best use of my efforts, I've decided to stop maintaining a comprehensive catalyst calendar here on the BiotechDueDiligence site. The information that I have published on the Upcoming Events will continue to be available going forward in a number of different ways:
Comments or Questions? Please email me!
Have you heard about Chimera Research Group, a research firm that published insightful and actionable commentary on topics related to biopharmaceutical investing? If you have been thinking about checking out our service, now is the perfect time.
To make sure 2012 gets off to a terrific start, you can currently take advantage of this special offer:
Your support is greatly appreciated